IJ Therapeutics

IJ Therapeutics is a pre-clinical stage biotechnology company dedicated to developing next-generation multi-specific antibodies for the treatment of cancer. The company leverages its proprietary Immuno-Junction platform to design therapies that precisely bridge immune effector cells with tumor cells, enhancing the immune system's ability to eradicate malignancies. Founded by industry veterans with extensive experience in antibody engineering, IJ Therapeutics aims to overcome the limitations of current immunotherapies by improving potency and reducing off-target toxicities. The company's lead programs focus on creating high-affinity, multi-valent interactions that can overcome tumor heterogeneity. Headquartered in South San Francisco, the firm is currently advancing a pipeline of novel candidates targeting various solid tumors.